Resources

She jokes that she “just can’t seem to lose that extra baby weight” after giving birth 3 years ago. However, her daughter recently started preschool, so she has been able to go to her new gym several times per week. In fact, one of the added bonuses of her membership is the free, weekly nutrition and exercise support groups. In addition to her routine labs, you order an A1C, which comes back elevated at 7.1%. This measurement is confirmed several days later. Based on Mrs. Hunter’s profile, you encourage lifestyle modifications and start metformin with an A1c target of less than 7%. After four years of good glycemic control with metformin 1500 mg q day, Mrs. Hunter returns for her 6-month follow-up visit. At this time, her office A1C is 8.2% and she has gained 7 pounds. She is very concerned about her weight gain. If weight is a concern, what would be the best antiglycemic drug to add to her regimen? Select one answer: A. A sulfonylurea B. A DPP-4 inhibitor C. A thiazolidinedione D. A GLP-1 receptor agonist Follow the link to see if you're right!

In this week’s Homerun Slides, understanding C-Reactive proteins and the conditions associated with increased and decreased CRP.

Type 2 diabetes was historically a rare occurrence in children but recent studies have reported marked increases in the prevalence of T2DM in children. Type 2 diabetes was first reported in a population-based study in 1979 of American Indian children in Arizona. This American Indian community has one of the highest rates of T2DM in adults and obesity in both adults and children.

In the conclusion of this Exclusive Interview, Dr. Rhinehart explains the necessity of taking the care of individuals into consideration when setting general health guidelines for the management of diabetes.

A professional society looks into how much physical activity is good for a healthy lifestyle.

What will be the impact of the new biosimilar insulins now in development?

A sedentary lifestyle may lead to type 2 diabetes and metabolic syndrome.

Empagliflozin is proving to be a strong proponent for monotherapy in patients with T2DM.

Could study of FOXO transcription factors one day lead to new therapies?

Conversion to pancreatic cells may lead to new cell replacement therapies.